The Prognostic Impact of Variant Allele Frequency (VAF) in TP53 Mutant Patients With MDS: A Systematic Review and Meta-Analysis - PubMed

The Prognostic Impact of Variant Allele Frequency (VAF) in TP53 Mutant Patients With MDS: A Systematic Review and Meta-Analysis - PubMed

The Prognostic Impact of Variant Allele Frequency (VAF) in TP53 Mutant Patients With MDS: A Systematic Review and Meta-Analysis

Jili Deng 1, Xia Wu 1, Yantao Ling 1, Xiaoyan Liu 1, Xue Zheng 1, Wu Ye 1, Gong Yuping 1

Affiliations 

• PMID: 32621334
 
• DOI: 10.1111/ejh.13483

Abstract

1.Our study is the first to analyze the genomic intra-difference of the prognostic impact of VAF in TP53 gene mutant MDS patients. 2. The results of our meta-analysis, including 13 cohorts of 11 studies, revealed that TP53 high VAF is an independent, adverse prognostic factor for OS in MDS patients. 3.We believe that the subset of patients with low allele mutation frequencies should be given more aggressive treatment strategies to achieve a better prognosis and longer survival. At the same time, the high mutation frequency part should result in early intervention and aggressive treatment for some patients.

Keywords: MDS; TP53; gene mutation; prognostic impact; survival; variant allele frequency (VAF).

This article is protected by copyright. All rights reserved.

Similar articles

• Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

  Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E.Leukemia. 2016 Mar;30(3):666-73. doi: 10.1038/leu.2015.304. Epub 2015 Oct 30.PMID: 26514544
• Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

  Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G.Blood Adv. 2020 Feb 11;4(3):482-495. doi: 10.1182/bloodadvances.2019001101.PMID: 32027746 Free PMC article.
• [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].

  Cai YN, Xu ZF, Li B, Qin TJ, Pan LJ, Qu SQ, Hu NB, Liu D, Huang HJ, Shi ZX, Zhang YD, Xiao ZJ.Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):379-386. doi: 10.3760/cma.j.issn.0253-2727.2020.05.004.PMID: 32536134 Chinese.
• The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.

  Fisher OM, Lord SJ, Falkenback D, Clemons NJ, Eslick GD, Lord RV.Gut. 2017 Mar;66(3):399-410. doi: 10.1136/gutjnl-2015-310888. Epub 2016 Jan 5.PMID: 26733670 Free PMC article. Review.
• Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.

  Arbab Jafari P, Ayatollahi H, Sadeghi R, Sheikhi M, Asghari A.Hematology. 2018 Dec;23(10):778-784. doi: 10.1080/10245332.2018.1471794. Epub 2018 May 14.PMID: 29757120 Review.
•